If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the clinical trial design of the Reyvow® (lasmiditan) CENTURION study
CENTURION was a phase 3 double-blind, placebo-controlled study that evaluated the first attack efficacy, consistency of response, and safety of Reyvow® (lasmiditan) in the acute treatment of 4 migraine attacks with or without aura.
Date of Last Review: September 13, 2023
Document Number: VV-MED-144872